Product
name: gp100 (210M) peptide
Sequence:
IMDQVPFSV
Purity: 95% by
HPLC
Counter
ion: Trifluoacetate
Format: Lyophilized
powder
Description: A peptide derived from gp100
(a lineage-restricted antigen) has been synthesized in a mutated (heteroclitic)
form for the purpose of enhancing HLA-A2.1 binding. This peptide,
gp100:209-217(210M) binds with a higher affinity to HLA-A2 than the native
peptide and induces better T-cell stimulation in vitro and in vivo. Initial
clinical trials at the National Cancer Institute (NCI) with 210M demonstrated
induction in peripheral blood of peptide- and tumor-specific cytotoxic
T-lymphocyte responses in 10 of 11 patients with HLA-A2.1–positive melanoma,
although no definitive antitumor activity was
observed.
Usage: For
Scientific Research Use Only, Not for Human Use.
Reference:
PLoS One. 2014;
9(4): e93231.
J Clin Oncol.
2008 May 10;26(14):2292-8.